Alamar Biosciences, Inc. (ALMR)
NASDAQ: ALMR · Real-Time Price · USD
25.92
-0.77 (-2.88%)
Apr 28, 2026, 2:43 PM EDT - Market open
Alamar Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Revenue | 74.21 | 25.14 |
| Revenue Growth (YoY) | 195.17% | - |
| Cost of Revenue | 32.51 | 16.54 |
| Gross Profit | 41.71 | 8.61 |
| Selling, General & Admin | 35.57 | 18.94 |
| Research & Development | 37.47 | 39.23 |
| Operating Expenses | 73.04 | 58.18 |
| Operating Income | -31.33 | -49.57 |
| Interest Expense | -0.4 | -2.08 |
| Interest & Investment Income | 2.16 | 4.68 |
| Currency Exchange Gain (Loss) | 0.42 | -0.09 |
| Pretax Income | -29.15 | -47.06 |
| Income Tax Expense | 0.67 | 0.01 |
| Net Income | -29.82 | -47.07 |
| Preferred Dividends & Other Adjustments | - | -0.8 |
| Net Income to Common | -29.82 | -46.27 |
| Shares Outstanding (Basic) | 28 | 25 |
| Shares Outstanding (Diluted) | 28 | 29 |
| Shares Change (YoY) | -2.89% | - |
| EPS (Basic) | -1.07 | -1.82 |
| EPS (Diluted) | -1.07 | -1.90 |
| Free Cash Flow | -58.98 | -58.16 |
| Free Cash Flow Per Share | -2.11 | -2.02 |
| Gross Margin | 56.20% | 34.23% |
| Operating Margin | -42.22% | -197.15% |
| Profit Margin | -40.18% | -184.03% |
| Free Cash Flow Margin | -79.48% | -231.33% |
| EBITDA | -28.57 | -47.27 |
| EBITDA Margin | -38.50% | -188.03% |
| D&A For EBITDA | 2.76 | 2.29 |
| EBIT | -31.33 | -49.57 |
| EBIT Margin | -42.22% | -197.15% |
| Revenue as Reported | 74.21 | 25.14 |
| Advertising Expenses | 1.5 | 0.9 |
Source: S&P Capital IQ. Standard template.
Financial Sources.